Evidence map›Paper›PMID 40824432›Full record

ReviewDiscover nano2025

Advancing neuroimaging: novel manganese- and iron-based MRI contrast agents for cerebral ischemic diseases.

Xiaojuan Deng, Shaojun Liu, Zhiyong Li, Xinyu Guan, Min Jia, Jian Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaojuan DengDepartment of Radiology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, People's Republic of China.
Shaojun LiuCollege of Biomedical Engineering, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Zhiyong LiDepartment of Radiology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, People's Republic of China.
Xinyu GuanCollege of Biomedical Engineering, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Min JiaDepartment of Urology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, People's Republic of China.
Jian YangDepartment of Clinical Nutrition, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, People's Republic of China. jianyang@hospital.cqmu.edu.cn.

Funding

Chongqing Key Clinical Specialty Construction Project SLCZDZK202202Chongqing Municipal Natural Science Foundation CSTB2022NSCQ-MSX0113National Natural Science Foundation of Chongqing cstc2021jcyj-msxmX0117
6 · The paper itself

Abstract

Cerebral ischemic diseases remain a significant clinical challenge, necessitating advancements in imaging technologies to improve diagnosis and therapeutic monitoring. This review highlights the limitations of gadolinium-based contrast agents (GBCAs), particularly their nephrotoxicity and limited specificity, and explores the emerging role of manganese- and iron-based MRI contrast agents as promising alternatives. Manganese-based agents demonstrate exceptional sensitivity to neuronal activity and metabolic changes, making them highly effective for assessing functional and cellular dynamics. Meanwhile, iron-based agents leverage their superparamagnetic properties to enhance ischemic lesion detection, particularly in T

Indexed as

Cerebral ischemicIron-based MRI contrast agentsMagnetic resonance imagingManganese-based MRI contrast agentsTheranostic

Identifiers

PMID40824432
PMCPMC12361001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.